(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of 21.58% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Arcus Biosciences's revenue in 2025 is $141,000,000.On average, 4 Wall Street analysts forecast RCUS's revenue for 2025 to be $9,733,491,311, with the lowest RCUS revenue forecast at $9,286,126,603, and the highest RCUS revenue forecast at $10,906,169,214. On average, 5 Wall Street analysts forecast RCUS's revenue for 2026 to be $16,026,986,258, with the lowest RCUS revenue forecast at $4,658,946,072, and the highest RCUS revenue forecast at $28,536,044,691.
In 2027, RCUS is forecast to generate $27,693,304,878 in revenue, with the lowest revenue forecast at $13,320,350,360 and the highest revenue forecast at $39,223,666,980.